A revolutionary inhaler designed to improve the chances of patients suffering from anaphylaxis and cardiac arrest will be further developed for export after its creators received a $100,000 Queensland Government grant.
Brisbane-based medical technology company De Motu Cordis Pty Ltd (DMC) is one of 70 Queensland companies to receive a grant in the latest round of the Ignite Ideas Fund, which helps start-ups and SMEs commercialise market-ready innovations and compete in the global market.
De Motu Cordis has developed a new inhaler to deliver drugs more rapidly and with less pain than traditional needle-based delivery methods.
The inhaler will be used to quickly deliver pulmonary drugs to patients who have heart attacks, and to deliver adrenaline to allergy patients suffering anaphylactic reactions.
Innovation Minister Kate Jones said De Motu would use the $100,000 grant to support clinical trials before it meets with the United States Food and Drug Agency (USFDA) and Australia’s Therapeutic Goods Administration (TGA) later this year.
‘We’re committed to investing in innovation to create sustainable jobs here in Queensland,’ Ms Jones said.
‘That’s why we’re committed to supporting companies like De Motu Cordis – not only have they developed a product that has the potential to help thousands of people around the world, they’re ready to scale up and start exporting.
‘Passing USFDA and TGA requirements will lead to the start of human trials next year.’
DMC Chief Operating Officer Tamara Mills said the company would soon head to the USA after being selected to take part in the prestigious TMCx program at Texas Medical Centre – the world’s largest – to accelerate US market access for the DMC product to treat anaphylaxis.
‘The Ignite Ideas grant will be used to support DMC in commercially developing the first non-invasive product for the rapid delivery of adrenaline,’ she said.
‘This will be the first of a number of critical and emergency care indications within DMC’s product portfolio.’
Research shows that delays in delivering adrenaline (eg because parents are reluctant to use epipen needles, or because of time taken to travel to hospital) can have major, long-term impacts on patients.
The De Motu inhaler aims to overcome these barriers so that people suffering from life-threatening allergies can received adrenaline more quickly before adverse effects set in.
De Motu Cordis is one of more than 70 Round 4 recipients sharing in more than $8.3 million in Ignite Ideas funding.
Supporting start-ups and innovation is one of the actions identified in the Queensland Trade and Investment Strategy 2017–2022.